PMID- 18540370
OWN - NLM
STAT- MEDLINE
DCOM- 20080729
LR  - 20110727
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 66
IP  - 6
DP  - 2008 Jun
TI  - [Apheresis therapy in Guillain-Barre syndrome].
PG  - 1195-9
AB  - Based on previous randomized controlled-trials (RCTs), plasma exchange (PE) has 
      been established as an effective treatment for Guillain-Barre syndrome (GBS). 
      Double filtration plasmapheresis (DFPP) and immunoadsorption plasmapheresis 
      (IAPP) may be effective for GBS, however their effectiveness have not been 
      established because any RCTs have not been available so far. Intravenous 
      immunoglobulin (IVIG) has also been established to be effective for GBS according 
      to several RCTs, however complications have been more frequent in PE than IVIG. 
      Therefore IVIg treatment should be considered as the first choice for GBS, and PE 
      treatment remains as the second-line if IVIg treatment is contraindicated.
FAU - Nagayama, Hiroshi
AU  - Nagayama H
AD  - Department of Internal Medicine, Nippon Medical School.
FAU - Katayama, Yasuo
AU  - Katayama Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
MH  - *Blood Component Removal
MH  - Guillain-Barre Syndrome/*therapy
MH  - Humans
MH  - Plasma Exchange
MH  - Plasmapheresis
RF  - 10
EDAT- 2008/06/11 09:00
MHDA- 2008/07/30 09:00
CRDT- 2008/06/11 09:00
PHST- 2008/06/11 09:00 [pubmed]
PHST- 2008/07/30 09:00 [medline]
PHST- 2008/06/11 09:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2008 Jun;66(6):1195-9.